Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

Clinical Pharmacokinetics

Volumn 42, Issue 3, 2003, Pages 293-301

  Dingemanse, Jasper ^a   Schaarschmidt, Dieter ^b   Van Giersbergen, Paul L M ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b PHAROS GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA HYDROXYACID SIMVASTATIN; BOSENTAN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYAMINO ACID; MEVINOLIN; PRAVASTATIN; RIFAMPICIN; RO 478634; RO 485033; RO 641056; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG RESEARCH; ENDOTHELIUM CELL; ENZYME INDUCTION; ENZYME SUBSTRATE COMPLEX; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SIMVASTATIN; SULFONAMIDES;

EID: 0344837894     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342030-00004     Document Type: Article

References (35)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endotbelial cells. Nature 1988; 332: 411-5
2. Ray A, Hegde LG, Chugh A, et al. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today 2000; 5: 455-64
3. Wu C. Recent discovery and development of endothelin receptor antagonists. Exp Opin Ther Patents 2000; 10: 1653-68
4. Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001; 43: 11-126
5. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-40
6. Cbakraharti S, Cukiemik M, Mukherjee S, et al. Therapeutic potential of endothelin receptor antagonists in diabetes. Expert Opin Investig Drugs 2000; 9: 2873-88
7. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-35
8. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996; 60: 124-37
9. Roux S, Breu V, Ertel SI, el al. Endothelin antagonism with hosentan: a review of potential applications. J Mol Med 1999; 77: 364-76
10. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23
11. Kiowski W, Suetsch G, Hunziker P, et al. Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-6
12. Suetsch G, Kjowski W, Yan X-W, et al. Short-term endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98: 2262-8
13. Weber C, Schmitt R, Birnboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999; 39: 703-14
14. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999; 27: 810-5
15. Smith DA. Induction and drug development. Eur J Pharm Sci 2000; 11: 185-9
16. Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 847-54
17. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32: 403-25
18. Prueksaritanont T, Gorham LM, Bennett MA, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-9
19. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202
20. Tucker GT, Houston JB, Huang S-M. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential: towards a consensus. Clin Pharmacol Ther 2001; 70: 103-14
21. Lausecker B, Hess B, Fischer G, et al. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 2000; 749: 67-83
22. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982
23. Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41: 1047-55
24. Van Giersbergen PLM, Treiber A, Clozel M, et al. In vitro and in vivo studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71: 253-62
25. Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002; 42: 283-9
26. Prueksaritanont T, Vega JM, Rogers JD, et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000; 40: 1274-9
27. Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183-92
28. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001; 18: 800-6
29. Weber C, Banken L, Birnboeck H, et al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999; 47: 701-6
30. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348-71
31. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28
32. Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592-7
33. Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987; 42: 388-94
34. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38: 493-504
35. Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001; 29: 615-22